8-K: Avid Bioservices to be Acquired by GHO Capital and Ampersand Capital Partners for $1.1 Billion

Avid Bioservices has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.

Summary

• Avid Bioservices has entered into a definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners.
• The all-cash transaction is valued at approximately $1.1 billion.
• Avid stockholders will receive $12.50 per share in cash.
• The per share purchase price represents a 13.8% premium to Avid's closing share price on November 6, 2024, and a 21.9% premium to the company's 20-day volume-weighted average share price.
• The transaction equates to an enterprise value of approximately $1.1 billion, a 6.3x multiple to consensus FY2025E revenue.
• The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions, including stockholder and regulatory approvals.
• The transaction is not subject to a financing condition.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the premium offered to shareholders and the backing of experienced private equity firms. The language used by management and the acquiring firms is optimistic about future growth and potential.

Positives

• The acquisition provides Avid stockholders with significant, immediate, and certain cash value for their shares.
• Partnering with GHO Capital and Ampersand Capital Partners will provide Avid with access to their knowledge base, network, and capital.
• The transaction is not subject to a financing condition, increasing the likelihood of closing.
• The acquisition price represents a premium to the recent trading price of Avid's stock.

Negatives

• Avid Bioservices will become a private company and its common stock will no longer be listed on any public stock exchange.
• The transaction is subject to customary closing conditions, including stockholder and regulatory approvals, which could potentially delay or prevent the closing.

Risks

• The transaction is subject to regulatory approvals, which could delay or prevent the closing.
• The transaction is subject to stockholder approval, which may not be obtained.
• There is a risk of unexpected costs or expenses resulting from the proposed transaction.
• The proposed transaction could have an adverse effect on the ability of the Company to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships.
• There is a risk of litigation relating to the proposed transaction.

Future Outlook

The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. Avid will operate as a private company under the same name and brand.

Management Comments

• Nick Green, president and CEO of Avid Bioservices, stated that now is the right time to move forward as a private company with new owners.
• Alan MacKay and Mike Mortimer, Managing Partners of GHO, expressed excitement about the acquisition and their ability to support Avid's management team.
• David Anderson, General Partner of Ampersand, stated that they look forward to leveraging their industry experience to drive growth at Avid.

Industry Context

This acquisition reflects the ongoing consolidation trend in the CDMO sector, with private equity firms seeking to capitalize on the growing demand for biologics manufacturing services. The deal highlights the attractiveness of companies with strong capabilities and growth potential in this space.

Comparison to Industry Standards

• The 6.3x multiple to consensus FY2025E revenue is within the range of recent transactions in the CDMO sector, although specific multiples vary based on factors such as growth rate, profitability, and technology.
• Comparable companies in the CDMO space include Catalent, Lonza, and Thermo Fisher Scientific, which have seen similar private equity interest and consolidation activity.
• The premium offered to Avid's share price is also consistent with typical acquisition premiums in the biopharmaceutical industry.

Stakeholder Impact

• Shareholders will receive a cash payment for their shares.
• Employees may experience changes in ownership and management.
• Customers and suppliers may see changes in the company's operations and strategy.
• The company will become private and no longer listed on a public exchange.

Next Steps

• Avid will file a proxy statement with the SEC.
• A special meeting of stockholders will be held to vote on the transaction.
• The companies will seek required regulatory approvals.
• The transaction is expected to close in the first quarter of 2025.

Key Dates

Keywords

acquisition, merger, CDMO, biologics, GHO Capital Partners, Ampersand Capital Partners, private equity, contract manufacturing, biopharmaceutical, takeover